Creatine for Depressed Male and Female Methamphetamine Users

Recruiting now · Phase 3

Conditions studied: Depression, Anxiety, Methamphetamine Dependence

In brief

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

Key facts

Study ID

NCT02568878

Run by

Montana State University

People needed

29

Starts

2015-11-01

Expected to finish

2017-05-01

Last updated by the study team

2015-12-11

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
• Current diagnosis of major depressive disorder (primary or substance-induced)
• Current diagnosis of an anxiety disorder (primary or substance-induced)
• Current Hamilton Depression Rating scale score > or = to 16
• Current Hamilton Anxiety Scale score > = to 18
• If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for > = to 4 weeks prior to creatine treatment initiation

You may not qualify if…

• Persons unable to provide adequate informed consent
• Persons who are at clinically significant suicidal or homicidal risk
• Primary substance-related diagnosis other than methamphetamine dependence or abuse
• Positive pregnancy test (females only)
• History of renal disease
• Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
• History of hypersensitivity reaction to creatine

Where it is running

• Montana State University College of Nursing (Missoula campus) — Missoula, Montana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.